Merck Patent Gmbh

Versum Materials Us, LLC

Merck Patent Gesellschaft MIT Beschraenkter Haftung

David Bruge

Frank Zenke

Dirk Finsinger

Kai Schiemann

Hans-Peter Buchstaller

Christiane Amendt

Wolfgang Staehle

Ulrich Emde

Dieter Dorsch

Holger Heil

Lars Lietzau

Sergei Vladimirovich Ivanov

Manfred Baumgarth

Hartmut Greiner

Christian Sirrenberg

Lars Thore Burgdorf

Christina Esdar

Margarita Wucherer-Plietker

Matthias Wiesner

Matthias Grell

Michal Krompiec

Ulrich Graedler

Maria Kordowicz

Ming Fang

Christoph Wetzel

Margarita Wucherer-plietker

The disclosed and claimed subject matter provides precursors having at least one tethered cyclopentadienyl ligand ('Cp ligand'), at least one amidinate ligand (“Ad ligand”) and a lanthanide and/or lanthanide-like transition metal (“M”) of the general formulae (i) (Cp ligand)-M-(Ad ligand) or (ii) (Cp ligand)-M-(Ad ligand).

Lanthanide and lanthanide-like transition metal complexes

Compounds of the formula I in which X, R, R, R, Rand Rhave the meanings indicated in Claim, are inhibitors of cell proliferation/cell vitality and can be employed for the treatment of tumours.

Pyrrolopyridinylpyrimidin-2-ylamine derivatives

Compounds of the formula (I), in which W, R, R, R, R, R, R, Rand Rhave the meanings indicated in Claim, can be employed, inter alia, for the treatment of tumors. 

Tetrahydroquinolines for use as modulators of the mitotic motor protein Eg5

Compounds of the formula I, in which s, k, I, W, R, R, R, and U have the meanings indicated in claim, can be employed, inter alia, for the treatment of tumours. 

Tetrahydroquinoline derivatives

Disclosed are compounds of formula (I), wherein W, R, R, R, R, R, R, R, and Rhave the meanings indicated in claim. Said compounds can be used for the treatment of tumors, among other things. 

Tetrahydroquinolines

The present invention relates to oxindoles of the formula I, their use as protein kinase activators or inhibitors, a method for their manufacture, their use for the preparation of a medicament for the treatment of diseases and their use for the manufacture of a pharmaceutical composition. 

Oxindoles as kinase inhibitors

Growing community of inventors

Frankfurt-am-Main, Germany

David Bruge